

Special Issue

Lung Cancer: Molecular Mechanisms and New Combination Strategies

Message from the Guest Editors

Lung cancer is the top cancer killer, covering non-small-cell lung cancer (NSCLC, ~85%) and small-cell lung cancer (SCLC). Advances include targeted drugs vs driver genes (EGFR, ALK, ROS1, RET, MET, KRAS, BRAF, HER2, NTRK, NRG1) and ICIs vs PD-1/PD-L1 & CTLA-4. Yet, most patients resist via bypass signaling, histologic shift, impaired antigen presentation, T-cell exhaustion, metabolic reprogramming, and immunosuppressive TME. This Issue seeks mechanistic insights & combos to prolong responses in both subtypes. We solicit research/reviews on:

- TKI+chemo (e.g., EGFR-TKI + platinum-pemetrexed) to curb resistance;
- ICI+chemo, anti-angiogenics, or dual checkpoint blockade;
- Bispecific Abs & T-cell engagers (e.g., PD-1×VEGF, DLL3×CD3);
- ADCs alone/combined;
- New ICIs (e.g., anti-TIGIT, anti-LAG-3);
- Perioperative & maintenance (neoadjuvant, adjuvant, metastatic);
- Resistance-overcoming tactics (epigenetic, metabolic, microbiome).

We welcome work on biomarkers, ctDNA, TME profiling, & preclinical models. Merging mechanistic, translational, & clinical data, this Issue aims to guide biomarker-driven selection & craft personalized lung cancer combos.

Guest Editors

Dr. Zhaohui Liao Arter

Division of Hematology/Oncology, Department of Medicine, Irvine School of Medicine, University of California, Irvine, CA, USA

Dr. Robert Hsu

Division of Medical Oncology, Department of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA

Deadline for manuscript submissions

31 March 2027



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/289112

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).